A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants
A Phase 1, Open-label, Parallel-group Study to Assess the Pharmacokinetics, Safety, and Tolerability of S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants
Sponsor: Shionogi
Listed as NCT05409911, this PHASE1 trial focuses on Hepatic Impairment and remains completed. Sponsored by Shionogi, it has been updated 8 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE1
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE1
-
Oct 2022 — Feb 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Oct 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shionogi
For direct contact, visit the study record on ClinicalTrials.gov .